The company specializes in creating clinically relevant in vitro human micro-tissue models using patient-derived material. These models are analyzed using OcellO's unique high throughput 3D imaging and phenotypic profiling technology, which provides measurements of cell growth and viability as well as more complex biology that correlates with clinical endpoints. This enables the selection of compounds with the optimum therapeutic or target-specific profile, improving the ranking of compounds in the early stages of drug development. OcellO welcomes partnerships and collaborations to speed up the selection and development of clients' lead compounds. Their imaging technology is designed to visualize and analyze small molecules and biologics in 3D cell culture, allowing for drug testing and screening in 3D-cultured human tissues such as organoids.